Cancer Vaccine Market By Product Type (Therapeutic Cancer Vaccines, Preventive Cancer Vaccines), By Cancer Type (Cervical Cancer, Prostate Cancer, Liver Cancer, Colorectal Cancer, Melanoma), By End-User (Hospitals, Research Institutes, Clinics, Cancer Centers), By Technology (DNA-Based Vaccines, Protein-Based Vaccines, Virus-Like Particle (VLP) Vaccines, Peptide-Based Vaccines), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Cancer Vaccine Market was valued at USD 11.0 Billion in 2024-e and will surpass USD 14.3 Billion by 2030; growing at a CAGR of 4.4% during 2025-2030.

The global cancer vaccine market has experienced significant growth in recent years, driven by increasing awareness of cancer prevention and advancements in immunotherapy. With the rising prevalence of cancer and the growing demand for innovative treatments, cancer vaccines are poised to play a pivotal role in oncology care. This market includes both preventive and therapeutic vaccines, aimed at either preventing cancer from developing or treating existing cancer by stimulating the body's immune system. As research continues to evolve, various cancer types, technologies, and delivery methods are being explored to enhance vaccine efficacy. The market is highly dynamic, with new innovations, strategic partnerships, and increasing investments contributing to its rapid expansion.

Therapeutic Cancer Vaccines Are Fastest Growing Owing to Immuno-Oncology Advancements

Among the two primary types of cancer vaccines, therapeutic cancer vaccines are the fastest growing segment. Unlike preventive vaccines, which are designed to prevent cancer in healthy individuals, therapeutic vaccines aim to treat existing cancer by boosting the immune system’s ability to recognize and destroy cancer cells. This segment has gained considerable momentum due to advancements in immuno-oncology, where the understanding of the tumor microenvironment and immune response has led to more effective therapeutic candidates. As the focus shifts toward personalized medicine, the demand for cancer vaccines that can specifically target tumor antigens has surged, further accelerating growth.

The success of immunotherapies such as checkpoint inhibitors and CAR-T cell therapies has also contributed to the growing interest in therapeutic vaccines. These vaccines are typically used in conjunction with other cancer treatments, enhancing the overall effectiveness of treatment regimens. Several companies are in the clinical trial stages of developing cancer vaccines that can target multiple tumor types, which further supports the expansion of this subsegment in the coming years.

Cervical Cancer Dominates the Cancer Type Subsegment

Cervical cancer remains the dominant cancer type targeted by vaccines, primarily due to the availability of highly effective vaccines like the HPV vaccine (human papillomavirus), which has shown significant success in preventing cervical cancer. Cervical cancer is one of the most common cancers among women, especially in low- and middle-income countries, where access to screening and preventive care may be limited. Vaccines targeting HPV have been proven to prevent the majority of cervical cancer cases, driving widespread adoption and global vaccination campaigns.

The success of the HPV vaccine, with its proven ability to reduce the incidence of cervical cancer, continues to fuel the dominance of this subsegment. In addition, the global push for more preventive healthcare measures has seen governments and health organizations promote vaccination programs. This has translated into a strong market presence for cervical cancer vaccines, particularly in developed regions with high healthcare access.

Hospitals Are Leading End-User Industry for Cancer Vaccines

The hospitals segment is the largest end-user industry for cancer vaccines. Hospitals play a pivotal role in administering both preventive and therapeutic cancer vaccines to patients as part of their cancer treatment or prevention programs. With increasing numbers of cancer patients seeking advanced treatment options, hospitals are seeing a rise in the number of patients receiving immuno-oncology treatments, including cancer vaccines.

Hospitals also offer the infrastructure required to manage clinical trials for cancer vaccines, which is essential for bringing new vaccines to market. Additionally, hospitals are integral to patient education and awareness, ensuring patients understand the importance of vaccination and the available options. As cancer diagnoses continue to rise, hospitals are expected to remain a key player in the distribution and administration of cancer vaccines, further strengthening this subsegment's position in the market.

DNA-Based Vaccines Are Leading the Technology Segment

DNA-based vaccines are the leading technology within the cancer vaccine market. This technology involves the introduction of a piece of genetic material into the body that codes for specific tumor-associated antigens, prompting an immune response. DNA vaccines have gained traction due to their ability to induce a robust immune response, their safety profile, and the relative ease of production compared to traditional vaccine technologies.

The DNA-based vaccine approach is highly versatile and can be tailored to target a wide array of cancer types. Companies in the oncology vaccine market are increasingly focused on optimizing DNA vaccine platforms to improve efficacy and target multiple antigens, thus broadening the scope of these vaccines. DNA-based vaccines also offer the potential for use in personalized cancer treatments, where vaccines can be designed to target specific mutations in a patient's tumor cells, further fueling the growth of this subsegment.

North America Dominates the Regional Market for Cancer Vaccines

North America holds the largest share of the cancer vaccine market, driven by a robust healthcare infrastructure, high cancer incidence rates, and substantial investments in cancer research and development. The United States, in particular, has been at the forefront of cancer vaccine development and adoption, with several FDA-approved vaccines already on the market, such as the HPV vaccine. Furthermore, the ongoing research into therapeutic cancer vaccines and immunotherapy options is expanding the market in North America.

Government initiatives, public health campaigns, and insurance coverage for cancer vaccines have also bolstered the adoption rate in North America. With continued advancements in biotechnology and oncology research, the region is expected to maintain its leadership position in the global cancer vaccine market.

Competitive Landscape: Leading Companies Driving Innovation

The competitive landscape of the cancer vaccine market is marked by significant contributions from key players, including Merck & Co., GlaxoSmithKline, Moderna, Pfizer, and BioNTech. These companies are at the forefront of developing new vaccine candidates, either through in-house research or collaborations with academic and research institutions. The focus is increasingly shifting toward personalized and combination therapies, with several companies exploring DNA and mRNA-based vaccines for cancer treatment.

Partnerships and acquisitions continue to play a crucial role in shaping the competitive dynamics. Leading companies are collaborating to enhance their research pipelines and expand their market reach, while smaller biotech firms bring innovation and new technologies to the table. As competition intensifies, companies are also focusing on obtaining regulatory approvals for new vaccines and addressing gaps in treatment efficacy to capture a larger share of the market.

List of Leading Companies:

• Merck & Co.
• GlaxoSmithKline (GSK)
• Roche
• Bristol-Myers Squibb
• Moderna
• Novavax
• Sanofi
• Pfizer
• Johnson & Johnson
• AstraZeneca
• BioNTech
• Valneva SE
• Advaxis, Inc.
• Emergent BioSolutions
• Inovio Pharmaceuticals

Recent Developments:

• Merck received FDA approval for its updated version of the cervical cancer vaccine, Gardasil 9, to provide extended protection against additional strains of HPV.
• Moderna has partnered with Merck to develop a personalized cancer vaccine based on mRNA technology to treat various types of cancers.
• Bristol-Myers Squibb announced positive Phase 3 trial results for its cancer vaccine aimed at melanoma, showing significant improvements in overall survival.
• BioNTech entered into a collaboration with Pfizer to develop novel mRNA-based cancer vaccines, targeting various solid tumors, with initial clinical trials set for next year.
• Sanofi completed the acquisition of Amunix Pharmaceuticals, which specializes in immune-oncology therapies, expanding its pipeline of cancer vaccine candidates.

Report Scope: